Consolidated Statements of Operations - USD ($)		12 Months Ended
		Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Pfizer collaboration revenue		$ 104,996,000	$ 22,354,000	$ 0
Total revenues		230,972,000	59,317,000	0
Collaboration expense to Pfizer		40,041,000	1,664,000	0
Selling, general and administrative	[1]	259,364,000	181,423,000	82,327,000
Research and development	[2]	107,403,000	136,713,000	192,560,000
Total operating costs and expenses		418,318,000	320,101,000	274,887,000
Loss from operations		(187,346,000)	(260,784,000)	(274,887,000)
Interest expense	[3]	13,971,000	10,401,000	12,663,000
Loss on extinguishment of debt		0	0	4,851,000
Interest income		(384,000)	(211,000)	(2,552,000)
Foreign currency transaction gain		0	(16,176,000)	(1,621,000)
Loss before income taxes		(200,933,000)	(254,798,000)	(288,228,000)
Income tax expense		5,048,000	336,000	761,000
Net loss		$ (205,981,000)	$ (255,134,000)	$ (288,989,000)
Net loss per common share - basic (in dollars per share)		$ (2.22)	$ (2.83)	$ (3.37)
Net loss per common share - diluted (in dollars per share)		$ (2.22)	$ (2.83)	$ (3.37)
Weighted average common share outstanding - basic (in shares)		92,974,887	90,036,459	85,839,303
Weighted average common share outstanding - diluted (in shares)		92,974,887	90,036,459	85,839,303
Product revenue, net
Revenues		$ 94,309,000	$ 3,630,000	$ 0
Cost of revenue		11,510,000	301,000	0
Richter license and milestone revenue
Revenues		$ 31,667,000	$ 33,333,000	$ 0

[1] Includes $4,842 and $5,330 of related party expense (inclusive of third-party pass-through costs) for the years ended March 31, 2022 and 2021, respectively

[2] Includes $58 of related party expense (inclusive of third-party pass-through costs) for the year ended March 31, 2021. There was no related party expense included in research and development expense for the year ended March 31, 2022

[3] Includes $11,551, $9,766, and $1,441 of interest expense under the Sumitomo Pharma Loan Agreement for the years ended March 31, 2022, 2021, and 2020, respectively